Akkermansia muciniphila and GLP-1 therapies form positive feedback loop for MASLD/MASH hepatoprotection

The global prevalence of Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is rapidly increasing, often progressing to Metabolic Dysfunction-Associated Steatohepatitis (MASH), which carries a high risk of cirrhosis and hepatocellular carcinoma. These conditions share underlying drivers like insulin resistance, visceral obesity, and chronic low-grade inflammation. While Glucagon-like peptide 1 (GLP-1)-based therapies have revolutionized T2DM and obesity management, their full pleiotropic mechanisms remain elusive. Concurrently, Akkermansia muciniphila has emerged as a key gut microbiota species with demonstrated hepatoprotective potential in preclinical MASLD/MASH models, suggesting a crucial link.

This narrative review systematically explored the bidirectional interactions between Akkermansia muciniphila and GLP-1-based therapies. A structured search of PubMed, Scopus, and Web of Science (last searched: 12 April 2026) was conducted using terms related to Akkermansia muciniphila, GLP-1 receptor agonists, MASLD/MASH, and T2DM. Of 174 identified records, 26 studies (23 preclinical, 3 clinical) were included after excluding 148 for duplication or irrelevance, directly addressing A. muciniphila and its interaction with GLP-1 pathways.

Preclinical evidence consistently demonstrates that liraglutide, semaglutide, exenatide, and tirzepatide increase Akkermansia muciniphila abundance. Conversely, A. muciniphila enhances endogenous GLP-1 secretion, specifically via the P9/ICAM-2 axis, suggesting a positive feedback loop. This bidirectional interaction positions A. muciniphila as both a target of GLP-1-mediated microbiome remodeling and an independent modulator of hepatoprotection.

This review synthesized 26 studies (23 preclinical, 3 clinical) to propose a working mechanistic model where GLP-1-based therapies remodel the gut microbiome by increasing A. muciniphila, which in turn boosts host GLP-1 production, contributing to improved metabolic health and hepatoprotection in MASLD/MASH.